Frédéric Triebel

Immutep Reveals a New Anti-LAG-3 Research Program

Retrieved on: 
Tuesday, June 8, 2021
Geography of Wales, Wales, Immutep, LAG3, Cardiff, Monash, Geography of the United Kingdom, Frédéric Triebel

Professor Andrea Brancale of Cardiff University also added: Our collaboration with Immutep is a great opportunity to combine a diverse set of skills from multiple teams in what is an exciting area of research.

Key Points: 
  • Professor Andrea Brancale of Cardiff University also added: Our collaboration with Immutep is a great opportunity to combine a diverse set of skills from multiple teams in what is an exciting area of research.
  • Under the Agreement, all intellectual property relating to lead compounds as well as derivatives thereof, will be jointly owned by Immutep and Cardiff University.
  • Immutep will have exclusive rights to develop and commercialise the new molecules in the clinic according to pre-defined licensing terms.
  • As announced on 31 August 2020, the Australian Research Council (ARC) awarded Immutep and research partner Monash University a grant under the ARCs Linkage Project scheme to support their research collaboration into LAG-3 for a further three years.

Immutep Announces Improving Results from Stage I of Phase II TACTI-002 Study

Retrieved on: 
Friday, September 18, 2020
Cancer treatments, Clinical medicine, Medicine, Immutep, Pembrolizumab, Lung cancer, Frédéric Triebel, Merck & Co., Head and neck cancer, Progression-free survival, Non-small-cell lung carcinoma, Eftilagimod alpha

TACTI-002 is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada).

Key Points: 
  • TACTI-002 is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada).
  • Immutep CSO and CMO, Dr Frederic Triebel said: The combination of efti and pembrolizumab is reporting encouraging progression free survival in patients with HNSCC and NSCLC, improving on the results from separate historical trials.
  • For example, in comparable studies, HNSCC patients receiving pembrolizumab monotherapy had a PFS of 2.1 months, or 2.3 months if given chemotherapy1,2.
  • This compares to a PFS of 4.3 months in HNSCC patients from the TACTI-002 trial, thus far.

Immutep Announces Improving Data from the Phase II TACTI-002 Study

Retrieved on: 
Monday, June 1, 2020
Cancer treatments, Clinical medicine, Cancer, Immutep, Lung cancer, Pembrolizumab, Non-small-cell lung carcinoma, Frédéric Triebel, Head and neck cancer

Improving Overall Response Rate (iORR) in HNSCC, increasing to 38.9% (previously 33% iORR)

Key Points: 
  • Improving Overall Response Rate (iORR) in HNSCC, increasing to 38.9% (previously 33% iORR)
    Progression free survival (PFS) continues to improve in 1st line non-small cell lung cancer (NSCLC) patients, estimated at more than 9 months
    SYDNEY, Australia, June 01, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces new interim data from its ongoing Phase II TACTI-002 study.
  • This data relates to the cut-off date of 4 May 2020 and shows improving efficacy results.
  • Immutep CSO and CMO, Dr Frederic Triebel said: TACTI-002 is generating increasingly promising data from both the NSCLC and HNSCC arms of study, as patients continue to receive efti in combination with KEYTRUDA.
  • The improving data in both HNSCC and NSCLC patients supports the use of efti in combination with pembrolizumab as a promising new therapeutic option for patients.

Immutep Global Webcast to Present New Data from 2020 ASCO Annual Meeting

Retrieved on: 
Wednesday, May 27, 2020
Medical specialties, Medicine, Immunology, Immutep, Eftilagimod alpha, LAG3, Autoimmunity, Antibody, Immune response, Frédéric Triebel

Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.

Key Points: 
  • Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
  • Immuteps current lead product candidate is eftilagimod alpha (efti or IMP321), a soluble LAG-3 protein (LAG-3Ig) based on the LAG-3 immune control mechanism.
  • Additional LAG-3 products, including antibodies, for immune response modulation in autoimmunity and cancer are being developed by Immuteps large pharmaceutical partners.

Immutep Reports Positive Phase II TACTI-002 Data

Retrieved on: 
Tuesday, April 28, 2020
Cancer treatments, Clinical medicine, Cancer, Immutep, Lung cancer, Pembrolizumab, Frédéric Triebel, Non-small-cell lung carcinoma, Merck & Co.

The data relates to the data cut-off date of 20 March 2020 and shows improving efficacy results.

Key Points: 
  • The data relates to the data cut-off date of 20 March 2020 and shows improving efficacy results.
  • TACTI-002 is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada).
  • Immutep CSO and CMO, Dr Frederic Triebel said: These very positive results for stage 1 demonstrate the benefits for NSCLC patients in receiving efti in combination with pembrolizumab.
  • Immutep CEO, Marc Voigt stated: Efti is showing remarkable results for patients with NSCLC and HNSCC.

Immutep Reports Positive TACTI-002 Data

Retrieved on: 
Wednesday, February 19, 2020
Cancer treatments, Clinical medicine, Medicine, Immutep, Eftilagimod alpha, Antineoplastic drugs, Breakthrough therapy, Lung cancer, Frédéric Triebel, Pembrolizumab, LAG3, Non-small-cell lung carcinoma

The Company will also present this interim data and provide a further update on its clinical programs in a global webcast, details below.

Key Points: 
  • The Company will also present this interim data and provide a further update on its clinical programs in a global webcast, details below.
  • The data relates to use of the Companys lead product candidate eftilagimod alpha (efti or IMP321), a soluble LAG-3 protein, as part of a combination treatment with pembrolizumab.
  • Immutep CSO and CMO, Dr Frederic Triebel said: The results we are seeing from our TACTI-002 trial are highly encouraging, with 47% of first line non-small cell lung cancer patients responding.
  • Immutep CEO, Marc Voigt stated: We are very excited by the results from TACTI-002 as pembrolizumab monotherapy is approved only for PD-L1 subgroups in first line NSCLC.

Lymphocyte Activation Gene 3 Protein, Pipeline Review, H2 2019 - Oncology, Cardiovascular, Ovarian Cancer, Hodgkin Lymphoma & Chronic Inflammation - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 16, 2020
Pharmaceutical, Health, Oncology, Clinical trials, Medical specialties, LAG3, Branches of biology, Medicine, Dendritic cell, Frédéric Triebel, HAVCR2

The "Lymphocyte Activation Gene 3 Protein - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lymphocyte Activation Gene 3 Protein - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Lymphocyte-activation gene 3 or LAG-3 is a protein encoded by the LAG3 gene.
  • It is involved in the maturation and activation of dendritic cells and lymphocyte activation.
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) pipeline Target constitutes close to 34 molecules.

Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data

Retrieved on: 
Thursday, September 26, 2019
Health, Medical specialties, Medicine, Immutep, Biotechnology, Frédéric Triebel, LAG3, Monoclonal antibody, Clinical trial, GSK2831781, Eftilagimod alpha

This staged approach of patient enrolment is based on, and is consistent with, the Simons two-stage clinical trial design.

Key Points: 
  • This staged approach of patient enrolment is based on, and is consistent with, the Simons two-stage clinical trial design.
  • Immutep CSO and CMO, Dr Frederic Triebel said: We are pleased with the recruitment of patients in the TACTI-002 clinical trial to date.
  • The trial is a Phase II, Simons two-stage, non-comparative, open-label, single-arm, multicentre clinical study that is taking place in up to 13 study centres across the U.S., Europe and Australia.
  • Immutep is also developing a best-and-first-in-class LAG-3 agonist monoclonal antibody for autoimmune diseases (IMP761) that is currently in preclinical development.